The U.S. Department of Health and Human Services (HHS) has awarded Moderna $590 million to accelerate the development and clinical trials of a vaccine targeting avian influenza, commonly known as bird flu. This funding aims to expedite the availability of a vaccine to combat potential future outbreaks, especially given the ongoing concerns about the virus’s potential to jump to humans. The grant supports late-stage clinical trials and associated manufacturing enhancements.
Tag: Moderna
U.S. Health Department Invests $590 Million in Moderna’s Bird Flu Vaccine Trial
The U.S. Department of Health and Human Services (HHS) has awarded Moderna Inc. a $590 million contract to accelerate the development and manufacturing of a vaccine against the avian influenza, also known as bird flu. This investment is part of the government’s efforts to bolster the nation’s pandemic preparedness.
Federal Funding Allocated to Moderna for Avian Influenza Vaccine Development
The U.S. Department of Health and Human Services (HHS) has awarded Moderna $590 million to expedite clinical trials and enhance manufacturing capabilities for a vaccine against avian influenza, commonly known as bird flu. This funding aims to bolster preparedness for potential future outbreaks of the virus in humans.
Moderna Granted $590M to Advance mRNA-based Avian Flu Vaccine Development
The US Department of Health and Human Services (HHS) has provided Moderna with a $590 million investment to hasten the development of an mRNA-based avian flu vaccine. This move aims to bolster global preparedness in case of a potential pandemic caused by the lethal bird flu virus.
Moderna Secures 590 Million Dollars for Accelerated Development of mRNA Bird Flu Vaccine
Moderna, a leading biotechnology company, has received a substantial financial boost from the US Department of Health & Human Services (HHS) to speed up the development of an mRNA-based vaccine for bird flu. The award amounts to approximately 590 million dollars, fueling research and production efforts to combat the potential outbreak of a human pandemic.
Moderna’s Stock Decline Linked to Disappointing COVID-19 Vaccine Projections
Moderna’s stock experienced a significant drop today following the company’s announcement of lower-than-expected forecasts for its COVID-19 vaccine sales. The pharmaceutical company cited various factors contributing to the revised projections, including changing market dynamics and increased competition. Investors reacted swiftly to the news, leading to a notable decline in share prices.